532 related articles for article (PubMed ID: 19427988)
21. Intravitreal triamcinalone acetonide for refractory uveitic cystoid macular oedema: longterm management and outcome.
Angunawela RI; Heatley CJ; Williamson TH; Spalton DJ; Graham EM; Antcliffe RJ; Stanford MR
Acta Ophthalmol Scand; 2005 Oct; 83(5):595-9. PubMed ID: 16187999
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
Dadgostar H; Ventura AA; Chung JY; Sharma S; Kaiser PK
Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
[TBL] [Abstract][Full Text] [Related]
23. Optical coherence tomography-guided ranibizumab injection for cystoid macular edema in well-controlled uveitis: twelve-month outcomes.
Reddy AK; Cabrera M; Yeh S; Davis JL; Albini TA
Retina; 2014 Dec; 34(12):2431-8. PubMed ID: 25170857
[TBL] [Abstract][Full Text] [Related]
24. Infliximab for chronic cystoid macular edema associated with uveitis.
Markomichelakis NN; Theodossiadis PG; Pantelia E; Papaefthimiou S; Theodossiadis GP; Sfikakis PP
Am J Ophthalmol; 2004 Oct; 138(4):648-50. PubMed ID: 15488796
[TBL] [Abstract][Full Text] [Related]
25. Long-term visual outcomes of intravitreal bevacizumab in inflammatory ocular neovascularization.
Mansour AM; Arevalo JF; Ziemssen F; Mehio-Sibai A; Mackensen F; Adan A; Chan WM; Ness T; Banker AS; Dodwell D; Chau Tran TH; Fardeau C; Lehoang P; Mahendradas P; Berrocal M; Tabbarah Z; Hrisomalos N; Hrisomalos F; Al-Salem K; Guthoff R
Am J Ophthalmol; 2009 Aug; 148(2):310-316.e2. PubMed ID: 19427992
[TBL] [Abstract][Full Text] [Related]
26. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema.
Nguyen QD; Tatlipinar S; Shah SM; Haller JA; Quinlan E; Sung J; Zimmer-Galler I; Do DV; Campochiaro PA
Am J Ophthalmol; 2006 Dec; 142(6):961-9. PubMed ID: 17046701
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia.
Lai TY; Chan WM; Liu DT; Lam DS
Retina; 2009 Jun; 29(6):750-6. PubMed ID: 19357555
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of ranibizumab-induced changes in high-resolution optical coherence tomographic retinal morphology and their impact on visual function.
Kiss CG; Geitzenauer W; Simader C; Gregori G; Schmidt-Erfurth U
Invest Ophthalmol Vis Sci; 2009 May; 50(5):2376-83. PubMed ID: 19136707
[TBL] [Abstract][Full Text] [Related]
29. Ranibizumab for treatment of choroidal neovascularization secondary to age-related macular degeneration.
Bhatnagar P; Spaide RF; Takahashi BS; Peragallo JH; Freund KB; Klancnik JM; Cooney MJ; Slakter JS; Sorenson JA; Yannuzzi LA
Retina; 2007 Sep; 27(7):846-50. PubMed ID: 17891007
[TBL] [Abstract][Full Text] [Related]
30. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
31. Bevacizumab vs ranibizumab for age-related macular degeneration: early results of a prospective double-masked, randomized clinical trial.
Subramanian ML; Ness S; Abedi G; Ahmed E; Daly M; Feinberg E; Bhatia S; Patel P; Nguyen M; Houranieh A
Am J Ophthalmol; 2009 Dec; 148(6):875-82.e1. PubMed ID: 19800611
[TBL] [Abstract][Full Text] [Related]
32. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography.
Markomichelakis NN; Halkiadakis I; Pantelia E; Peponis V; Patelis A; Theodossiadis P; Theodossiadis G
Ophthalmology; 2004 May; 111(5):946-53. PubMed ID: 15121373
[TBL] [Abstract][Full Text] [Related]
33. Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.
Heier JS; Campochiaro PA; Yau L; Li Z; Saroj N; Rubio RG; Lai P
Ophthalmology; 2012 Apr; 119(4):802-9. PubMed ID: 22301066
[TBL] [Abstract][Full Text] [Related]
34. Intravitreal bevacizumab in refractory uveitic macular edema: one-year follow-up.
Cervantes-Castañeda RA; Giuliari GP; Gallagher MJ; Yilmaz T; MacDonell RE; Quinones K; Foster CS
Eur J Ophthalmol; 2009; 19(4):622-9. PubMed ID: 19551679
[TBL] [Abstract][Full Text] [Related]
35. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion.
Chang LK; Spaide RF; Klancnik JM; Sorenson J; Slakter JS; Freund KB; Yannuzzi LA; Tseng JJ; Klein R
Retina; 2011 May; 31(5):821-8. PubMed ID: 21317833
[TBL] [Abstract][Full Text] [Related]
36. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study.
Campochiaro PA; Brown DM; Awh CC; Lee SY; Gray S; Saroj N; Murahashi WY; Rubio RG
Ophthalmology; 2011 Oct; 118(10):2041-9. PubMed ID: 21715011
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of intravitreal bevacizumab in treating postoperative pseudophakic cystoid macular edema.
Spitzer MS; Ziemssen F; Yoeruek E; Petermeier K; Aisenbrey S; Szurman P
J Cataract Refract Surg; 2008 Jan; 34(1):70-5. PubMed ID: 18165084
[TBL] [Abstract][Full Text] [Related]
38. Therapeutic interventions for macular diseases show characteristic effects on near and distance visual function.
Munk M; Kiss C; Huf W; Sulzbacher F; Bolz M; Sayegh R; Eisenkölbl S; Simader C; Schmidt-Erfurth U
Retina; 2013 Oct; 33(9):1915-22. PubMed ID: 23584693
[TBL] [Abstract][Full Text] [Related]
39. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting.
Cohen SY; Dubois L; Tadayoni R; Fajnkuchen F; Nghiem-Buffet S; Delahaye-Mazza C; Guiberteau B; Quentel G
Am J Ophthalmol; 2009 Sep; 148(3):409-13. PubMed ID: 19477713
[TBL] [Abstract][Full Text] [Related]
40. Fluocinolone acetonide sustained drug delivery device for chronic central retinal vein occlusion: 12-month results.
Ramchandran RS; Fekrat S; Stinnett SS; Jaffe GJ
Am J Ophthalmol; 2008 Aug; 146(2):285-291. PubMed ID: 18533125
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
